Cantor Fitzgerald Analysts Give Arrowhead Pharmaceuticals (ARWR) a $5.00 Price Target

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has been assigned a $5.00 target price by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday, MarketBeat reports. The firm currently has a “neutral” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target suggests a potential downside of 5.84% from the stock’s previous close.

Several other research firms have also commented on ARWR. Chardan Capital reissued a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 16th. ValuEngine raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. BidaskClub raised shares of Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 18th. B. Riley assumed coverage on shares of Arrowhead Pharmaceuticals in a research report on Friday, January 5th. They set a “neutral” rating and a $3.00 price target for the company. Finally, Piper Jaffray Companies raised shares of Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price target for the company in a research report on Monday, November 27th. Five equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $4.13.

Arrowhead Pharmaceuticals (NASDAQ ARWR) traded down $0.28 during trading hours on Monday, reaching $5.31. 1,626,986 shares of the company were exchanged, compared to its average volume of 2,270,000. Arrowhead Pharmaceuticals has a 52 week low of $1.42 and a 52 week high of $6.75. The stock has a market capitalization of $397.34, a price-to-earnings ratio of -11.30 and a beta of 2.52. The company has a current ratio of 3.63, a quick ratio of 3.63 and a debt-to-equity ratio of 0.03.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Tuesday, December 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.02). Arrowhead Pharmaceuticals had a negative return on equity of 40.38% and a negative net margin of 116.17%. The business had revenue of $8.71 million during the quarter, compared to analysts’ expectations of $7.32 million. sell-side analysts predict that Arrowhead Pharmaceuticals will post -0.74 EPS for the current fiscal year.

In other Arrowhead Pharmaceuticals news, COO Bruce D. Given sold 20,000 shares of the stock in a transaction dated Monday, January 1st. The shares were sold at an average price of $3.69, for a total transaction of $73,800.00. Following the completion of the sale, the chief operating officer now directly owns 948,356 shares of the company’s stock, valued at $3,499,433.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 4.60% of the company’s stock.

Several institutional investors have recently made changes to their positions in ARWR. Virtu KCG Holdings LLC raised its position in shares of Arrowhead Pharmaceuticals by 115.6% in the 2nd quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 53,215 shares during the last quarter. ING Groep NV purchased a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $3,500,000. Schwab Charles Investment Management Inc. raised its position in shares of Arrowhead Pharmaceuticals by 10.4% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock valued at $742,000 after purchasing an additional 16,103 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Arrowhead Pharmaceuticals by 252.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 31,765 shares during the last quarter. Finally, Allianz Asset Management GmbH purchased a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $1,958,000. 20.48% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Cantor Fitzgerald Analysts Give Arrowhead Pharmaceuticals (ARWR) a $5.00 Price Target” was first published by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/12/cantor-fitzgerald-analysts-give-arrowhead-pharmaceuticals-arwr-a-5-00-price-target.html.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply